Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 7/20 | 0.89 |
| ▸ | ESR2 known ✓ | Q92731 | 6/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.89 |
| ▸ | SHBG | P04278 | 3/20 | 0.89 |
| ▸ | PGR | P06401 | 3/20 | 0.89 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.89 |
| ▸ | AR | P10275 | 3/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.89 |
| ▸ | SNCA | P37840 | 3/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.89 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.89 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.89 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.89 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.65 |
| ▸ | STS | P08842 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL10412523 | 1.00 | ESR1 (0.89) | ESR1ESR2LMNAHIF1ASHBG | |
| Estriol SCHEMBL7992695 | 0.99 | ESR1 (0.87) | ESR1ESR2LMNAHIF1ASHBG | |
| Estriol SCHEMBL345572 | 0.96 | ESR1 (0.85) | ESR1ESR2LMNAHIF1ASHBG | |
| Epiestriol SCHEMBL221084 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ASHBG | |
| Estriol SCHEMBL13123063 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ASHBG | |
| Estriol SCHEMBL23743979 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ASHBG | |
| Estriol SCHEMBL223196 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ASHBG | |
| Estriol SCHEMBL12180048 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ASHBG | |
| Estriol SCHEMBL4896486 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ASHBG | |
| Estriol SCHEMBL223226 | 0.94 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ASHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| EP-4608876-A2 | ENDOCYTIC AGENTS | BioVentures, LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-3277285-B1 | ESTRIOL FOR REDUCING CORTICAL GRAY MATTER ATROPHY | UNIV CALIFORNIA (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4103160-B1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZUERICH (CH) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024092274-A2 | ENDOCYTIC AGENTS | BIOVENTURES, LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11865122-B2 | Estrogen therapy for brain gray matter atrophy and associated disability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023223235-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | PURNA PHARMACEUTICALS NV (BE) | 2023-11-23 | — | — | WO | disclosed |
| EP-3137088-B1 | PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY FOR THE TREATMENT OF MULTIPLE SCLEROSIS | UNIV CALIFORNIA (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3200802-B1 | COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION | UNIV CALIFORNIA (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230080270-A1 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | ETH ZURICH (CH) | 2023-03-16 | — | — | US | disclosed |
| WO-2016160830-A1 | METHODS OF PROVIDING NEUROPROTECTIVE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016160832-A1 | METHODS OF MONITORING ESTRIOL THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016053946-A1 | COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016036719-A1 | ESTROGEN THERAPY FOR BRAIN GRAY MATTER ATROPHY AND ASSOCIATED DISABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2015168002-A1 | PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168000-A1 | ESTROGEN COMBINATION FOR TREATMENT OF MULTIPLE SCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-11-05 | — | — | WO | disclosed |
| US-6855703-B1 | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds | ENDEAVOR PHARMACEUTICALS (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1267852-A2 | PHARMACEUTICAL COMPOSITIONS OF CONJUGATED ESTROGENS AND METHODS OF ANALYZING MIXTURES CONTAINING ESTROGENIC COMPOUNDS | Endeavor Pharmaceuticals (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001068074-A2 | PHARMACEUTICAL COMPOSITIONS OF CONJUGATED ESTROGENS AND METHODS OF ANALYZING MIXTURES CONTAINING ESTROGENIC COMPOUNDS | ENDEAVOR PHARMACEUTICALS (US) | 2001-09-20 | — | — | WO | disclosed |
| EP-0200960-A1 | Total estriol fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | ESR1 188/4885ESR2 274/4885LMNA 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.